These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19068212)

  • 21. Molecular modeling of interactions of dihydropyridines and phenylalkylamines with the inner pore of the L-type Ca2+ channel.
    Lipkind GM; Fozzard HA
    Mol Pharmacol; 2003 Mar; 63(3):499-511. PubMed ID: 12606756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.
    Yamamoto T; Niwa S; Ohno S; Onishi T; Matsueda H; Koganei H; Uneyama H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2006 Feb; 16(4):798-802. PubMed ID: 16309909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.
    Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the direct negative dromotropic effect of a new calcium channel blocker, cilnidipine, with that of nicardipine.
    Sugiyama A; Satoh Y; Takahara A; Ando K; Nakamura Y; Hashimoto K
    Heart Vessels; 2005 May; 20(3):112-5. PubMed ID: 15912307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of human equilibrative nucleoside transporters by dihydropyridine-type calcium channel antagonists.
    Li RW; Tse CM; Man RY; Vanhoutte PM; Leung GP
    Eur J Pharmacol; 2007 Jul; 568(1-3):75-82. PubMed ID: 17512522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of some 1,4-dihydropyridine Ca antagonists on the blast transformation of rat spleen lymphocytes.
    Briede J; Daija D; Bisenieks E; Makarova N; Uldriķis J; Poikans J; Duburs G
    Cell Biochem Funct; 1999 Jun; 17(2):97-105. PubMed ID: 10377955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
    Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
    J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ca
    Toyoda F; Mesirca P; Dubel S; Ding WG; Striessnig J; Mangoni ME; Matsuura H
    Sci Rep; 2017 Aug; 7(1):7869. PubMed ID: 28801600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics.
    Kang S; Cooper G; Dunne SF; Luan CH; James Surmeier D; Silverman RB
    Bioorg Med Chem; 2013 Jul; 21(14):4365-73. PubMed ID: 23688558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Calpastatin binds to a calmodulin-binding site of cardiac Cav1.2 Ca2+ channels.
    Saud ZA; Minobe E; Wang WY; Han DY; Horiuchi M; Hao LY; Kameyama M
    Biochem Biophys Res Commun; 2007 Dec; 364(2):372-7. PubMed ID: 17950697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing the 1,4-dihydropyridines binding interactions in the L-type Ca2+ channel: model construction and docking calculations.
    Cosconati S; Marinelli L; Lavecchia A; Novellino E
    J Med Chem; 2007 Apr; 50(7):1504-13. PubMed ID: 17335186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis, evaluation of pharmacological activities and quantitative structure-activity relationship studies of a novel group of bis(4-nitroaryl-1,4-dihyropyridine).
    Miri R; Javidnia K; Hemmateenejad B; Tabarzad M; Jafarpour M
    Chem Biol Drug Des; 2009 Feb; 73(2):225-35. PubMed ID: 19207425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular studies on the voltage dependence of dihydropyridine action on L-type Ca2+ channels. Critical involvement of tyrosine residues in motif IIIS6 and IVS6.
    Bodi I; Yamaguchi H; Hara M; He M; Schwartz A; Varadi G
    J Biol Chem; 1997 Oct; 272(40):24952-60. PubMed ID: 9312099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between neural networks (NN) and principal component analysis (PCA): structure activity relationships of 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues).
    Takahata Y; Costa MC; Gaudio AC
    J Chem Inf Comput Sci; 2003; 43(2):540-4. PubMed ID: 12653519
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of new N3-substituted dihydropyrimidine derivatives as L-/T- type calcium channel blockers.
    Teleb M; Zhang FX; Farghaly AM; Aboul Wafa OM; Fronczek FR; Zamponi GW; Fahmy H
    Eur J Med Chem; 2017 Jul; 134():52-61. PubMed ID: 28399450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The voltage-gated Ca(2+) channel is the Ca(2+) sensor protein of secretion.
    Hagalili Y; Bachnoff N; Atlas D
    Biochemistry; 2008 Dec; 47(52):13822-30. PubMed ID: 19061337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Azelnidipine treatment reduces the expression of Ca
    Nasu F; Obara Y; Okamoto Y; Yamaguchi H; Kurakami K; Norota I; Ishii K
    Life Sci; 2021 Mar; 269():119043. PubMed ID: 33453240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyridine inhibition of the glycine receptor: subunit selectivity and a molecular determinant of inhibition.
    Chen X; Cromer B; Webb TI; Yang Z; Hantke J; Harvey RJ; Parker MW; Lynch JW
    Neuropharmacology; 2009 Jan; 56(1):318-27. PubMed ID: 18657556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opposite effects of a single IIIS5 mutation on phenylalkylamine and dihydropyridine interaction with L-type Ca2+ channels.
    Huber IG; Wappl-Kornherr E; Sinnegger-Brauns MJ; Hoda JC; Walter-Bastl D; Striessnig J
    J Biol Chem; 2004 Dec; 279(53):55211-7. PubMed ID: 15504730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interaction of dihydropyridine calcium channel blockers with calmodulin and calmodulin inhibitors.
    Thayer SA; Fairhurst AS
    Mol Pharmacol; 1983 Jul; 24(1):6-9. PubMed ID: 6865927
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.